{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"46"}],"title":"Deterioration"},{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"26"}],"title":"Improved"},{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"76"}],"title":"Stable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"166"},{"groupId":"OG002","value":"148"}],"units":"Participants"}],"description":"The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) is a 30 question survey and includes 5 functional domain subscales, global health status/quality of life, disease/treatment related symptoms, and the perceived financial impact of disease. Higher scores are reflective of a greater presence of symptoms.","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis is based on the FAS. The FAS included all participants who were randomized. 'Number Analyzed' in represents number of participants in the FAS with a score at baseline and post-baseline.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1, Day 1 of each subsequent cycle, end of treatment/withdrawal visit and the 30, 60 and 90 days safety follow up visits, based on cutoff date: 19 September 2018.","title":"Number of Participants With Improved, Stable and Deterioration Based on 10-Point Change for EORTC QLQ-C30 Global QoL","type":"SECONDARY","unitOfMeasure":"Participants"}